Coronavirus Enfeksiyonu ve Kardiyovasküler Hastalıklar
Özet
COVID-19, SARS-CoV-2 virüsünün ACE2 reseptörlerine bağlanarak hücreye girmesiyle başlayan ve şiddetli sitokin fırtınası ile akciğerlerin yanı sıra kalp dokusunda da ciddi hasara yol açabilen bir enfeksiyondur. Hastalık sürecinde hipoksemi, aşırı inflamatuar reaksiyon ve ilaç etkileşimleri sonucunda akut miyokard hasarı, kalp yetmezliği, ritim bozuklukları ve tromboembolik olaylar gibi önemli kardiyovasküler komplikasyonlar gelişebilmektedir. Özellikle D-dimer yüksekliği ve koagülasyon bozuklukları mortalite riskini artırırken, hastaların takibinde yakın hemodinamik izlem ve uygun antikoagulan tedavisi hayati önem taşımaktadır.
COVID-19 is a viral infection that begins with the SARS-CoV-2 virus binding to ACE2 receptors, leading to severe cytokine storms and significant damage to both lung and cardiac tissues. During the disease course, cardiovascular complications such as acute myocardial injury, heart failure, arrhythmias, and thromboembolic events can develop due to hypoxemia, excessive inflammatory response, and drug interactions. Particularly, elevated D-dimer levels and coagulation disorders increase the risk of mortality, making close hemodynamic monitoring and appropriate anticoagulant therapy vital for patient management.
Referanslar
Ekim M, Er ZC, Alagha S,Relationship Between COVID-19 And Venous Thromboembolism. Gevher Nesibe Journal of Medical&Health Sciences ISSN 2717-7394. ArrivalDate: 04.08.2020|Published Date: 22.10.2020 2020, Vol: 5, Issue: 8 pp: 53-60 DoiNumber: http://dx.doi.org/10.46648/gnj.102
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 HospitalizedPatientsWith 2019 NovelCoronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7.
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl j Med. 2020;382:727-33.
Banerjee A, Kulcsar K, Misra V Batsandcoronaviruses. Viruses. 2019;11 doi: 10.3390/v11010041.
Yang D, Leibowitz JL. The structureand functions of coronavirusgenomic 3′ and 5′ ends. VirusRes. 2015;206:120–133. doi: 10.1016/j.virusres.2015.02.025.
Shereen MA, Khan S, Kazmi A. COVID-19 infection: Origin, transmission, andcharacteristics of human coronaviruses. J AdvRes 2020;24:91–8.
Ramaiah A, Arumugaswami V. In sights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immunedeterminantsforvaccinedevelopment. bioRxiv. 2020 Jan 30 doi: 10.1101/2020.01.29.925867.
Chan JF, Kok KH, Zhu Z, Genomic characterization of the 2019 novelhuman-pathogeniccoronavirusisolatedfrom a patient with atypical pneumonia after visitingWuhan. EmergMicrobesInfect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902.
Wu A, Peng Y, Huang B. Genome composition and divergence of thenovelcoronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325–328. doi: 10.1016/j.chom.2020.02.001.
Erdös EG. Angiotensin I convertingenzyme. CirculationResearch. 1975;36(2):247-55
Li M-Y, Li L, Zhang Y. Expression of the SARS-CoV-2 cellreceptor gene ACE2 in a widevariety of humantissues. Infectiousdiseases of poverty. 2020;9:1-7.
Lonsdale J, Thomas J, Salvatore M, et al. Thegenotype-tissueexpression (GTEx) project Nature genetics. 2013;45(6):580.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239–42.
Zhou F, Yu T, Du R. et al. Clinicalcourseand risk factorsformortality of adultinpatientswith COVID-19 in Wuhan, China: A retrospectivecohortstudy. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Huang C, Wang Y, Li X, et al. Clinicalfeatures of patientsinfectedwith 2019 novelcoronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
Xu, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. LancetRespir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘CytokineStorm′ in COVID-19. J Infect 2020;80:607–13
Chen D, Li X, Song Q, Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020. https:// doi.org/10.1101/2020.02.27.20028530.
Klausegger A, Strobl B, Regl G, Identification of a coronavirus hemagglutinin-esterasewith a substrate specificity different from those of influenza C virus and bovine coronavirus. J. Virol. 1999;73(5):3737-43. doi. org/10.1128/JVI.73.5.3737-3743.1999
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China, Nature. 2020;579(7798):265-9. doi.org/10.1038/s41586- 020-2008-3
Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implicationsfor SARS. Nat. Rev. Immunol. 2005;5(12):917-27. doi. org/10.1038/nri1732
Du Y, Tu L, Zhu P, et al. ClinicalFeatures of 85 FatalCases of COVID-19 fromWuhan: A Retrospective Observational Study, Am. J. Respir. Crit. CareMed. (2020). doi. org/10.1164/rccm.202003-0543OC [Epubahead of print].
Wang C, Xie J, Zhao L, et al. Aveolar macrophage activation and cytokinestorm in thepathogenesis of severe COVID-19. 2020 doi: 10.21203/rs.3.rs-19346/v1.
Zheng HY, Zhang Mi, Yang CX, et al. Elevate dexhaustion levels and reduced functional diversity of T cells in peripheral blood maypredict severe progression in COVID-19 patients. Cell MolImmunol. 2020;17(5):541–543. doi: 10.1038/s41423-020-0401-3.
LuluMa, MD,KaichengSong, MD, andYuguang Huang,MDCoronavirusDisease-2019(COVID-19) and Cardiovascular Complications J Cardiothroc Vasc Anesth. 2021 Jun; 35(6): 1860–1865
Deshotels MR, Xia H, Sriramula S, Lazartigues E, Angiotensin II mediates angiotensin converting enzyme type internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014;64:1368-75.
Xiong T.Y, Redwood S,Prendergast B.Coronavirusesandthecardiovascularsystem: acuteandlong-termimplications. EurHeart J. 2020
Li B. Yang J.Zhao F. Prevalenceandimpact of cardiovascularmetabolicdiseases on COVID-19 in China. ClinResCardiol. 2020
Andrew M. South, Debra I. Diz, and X Mark C. Chappell. COVID-19, ACE2, and the cardiovascular consequences. Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston-Salem, North Carolina Submitted 28 March 2020; accepted in final form 30 March 2020
Ishiyama Y, Gallagher P E, Averill DB, et al. Upregulation of angiotensinconvertingenzyme 2 aftermyocardialinfarctionbyblockade of angiotensin II receptors. Hypertension. 2004;43(5):970–6
Klimas J, Olvedy M, Ochodnicka Mackovicova K, et al. Perinatally administered losartan augmentsrenal ACE2 expression but not cardiacorrenal Mas receptor in spontaneously hypertensiverats. Journal of Cellular and Molecular Medicine. 2015;19(8):1965– 74.
Chaubey SK, Sinha AK, Phillips E, Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection. SexHealth 2009;6:254–7.
Mitra RL, Greenstein SA, Epstein LM. An algorithm form anaging QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possiblebenefits of intravenous lidocaine. HeartRhythm Case Rep. 2020;6(5):244–248. doi: 10.1016/j.hrcr.2020.03.016.
Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospitalmortality in patientswith COVID-19 in New York state. JAMA. 2020;323(24):2493–2502. doi: 10.1001/jama.2020.8630.
Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1–6. https://doi.org/10. 1001/jamacardio.2020.1096.
Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1–8.
Buzon J, Roignot O, Lemoine S, et al. Takotsubo Cardiomyopathy Triggered by Influenza A Virus. InternMed 2015;54:2017–9
Li Y, Liu T, Liu M, et al. Electrocardiogramicabnormities in patientswith COVID-19. Chin J Arhythmia (in Chinese) 2020 doi: 10.3760/cma.j.cn.113859-20200302-20200044.
Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. ZhonghuaXinXueGuanBingZaZhi. 2020;48(6):450–455. doi: 10.3760/cma.j.cn112148-20200220-00105.
Thygesen K, Alpert JS, Jaffe AS, et al. Executivegroup on behalf of the Joint European Society of Cardiology (ESC)/AmericanCollege of Cardiology (ACC)/AmericanHeartAssociation (AHA)/World Heart Federation (WHF) Task Force forthe Universal Definition of Myocardial Infarction. FourthUnivers Defí n MyocardInfarctGlobHeart 2018;13:305–38
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thromboticcomplications in criticallyill ICU patientswith COVID-19. ThrombRes 2020;191:145–7
Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Groupfor Covid-19. ClinicalCharacteristics of CoronavirusDisease 2019 in China. N Engl J Med 2020;382:1708–20.
Ünüvar A. COVID-19 ve koagülopati. Sağlık Bilimlerinde İleri Araştırmalar Dergisi.2020, 3 (Suppl.1): S53- S62.
COVID-19 (SARS-CoV-2 enfeksiyonu) Antisitokin-Antiinflamatuar Tedaviler, KoagülapatiT.C. SAĞLIK BAKANLIĞI 7 Kasım 2020 Bilimsel Danışma Kurulu Çalışması
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptivestudy. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/ S0140-6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076
Özbalcı D, Süleyman Demirel Üniversitesi İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı. AnticoagulantTherapy in COVID-19. Med J SDU / SDÜ Tıp Fak Derg u 2021:(özelsayı-1):37-45 doi: 10.17343/sdutfd.899521
Wiersinga WJ, Rhodes A, Cheng AC. Pathophysiology, transmission, diagnosis, andtreatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020;324(8):782-93.
Manolis AS, Manolis AA, Manolis TA, COVID-19 Infection and Cardiac Arrhythmias. TrendsCardiovascMed 2020;30(8):451-60.
Bansal M. Cardiovasculardiseaseand COVID-19. DiabetesMetabSyndr 2020;14(3):247-50.
